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CANCER, INFERTILITY, AND THE
NARRATIVE OF PROGRESS
Sarah Rodriguez*
The four essays preceding this one each focused on aspects of the
increasingly diverse and complicated area of reproduction. As the
concluding essay in this Symposium Issue, I will weave these essays
into my overview of cancer funding in the United States and my cri-
tique of the "progress against cancer" narrative.
Three of the essays examine fertility preservation for cancer pa-
tients to varying degrees, and so I will begin with the seeming outlier:
Arshagouni's Be Fruitful and Multiply, by Other Means, if Necessary:
The Time Has Come to Recognize and Enforce Gestational Surrogacy
Agreements, which is not explicitly about oncofertility. Rather, he ar-
gues for federal legalization of gestational surrogacy. A gestational
surrogate, he states, "provides a noble service that should be
respected and honored," and the fact that such an act is not honored
without "reservation" is, to Arshagouni, "mystifying."' Arshagouni
lays out at length the legal and moral arguments others have made
against allowing gestational surrogacy and makes his case for why
each of them comes up short. The compilation of studies he uses to
illustrate that some of the fears of those who argue against gestational
surrogacy-such as the fear that it will be detrimental to the child
born in such a manner-are so far unfounded, and his addressing
many of the legal and ethical concerns contributes to a more robust
debate about this practice. But in his effort to illustrate that this form
of reproduction is not the harmful or risky endeavor as argued by
others, he does not address the possibility of harm or risk. Reproduc-
tion, in all its old and more recent methods, is based within medical,
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1. Paul G. Arshagouni, Be Fruitful and Multiply, by Other Means, if Necessary: The Time Has
Come to Recognize and Enforce Gestational Surrogacy Agreements, 61 DEPAUL L. REv. 799, 847
(2012).
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legal, physiological, social, familial, and economic understandings and
relationships, making it an inherently complicated and complex
endeavor.
Though gestational motherhood is a possible resource for some
women who lose both their fertility and their capacity to bear a child
as a result of cancer treatment, the remaining three essays all centrally
concern fertility preservation and cancer treatment. Because of
changes in cancer treatment, many people within (or before) their
childbearing years who have cancer will either be cured or have their
lives significantly extended, and many within this population are con-
cerned about the impact their cancer treatments may have on their
future fertility.2 The preservation of fertility for young people before
they undergo potentially infertility-inducing cancer treatments is a
fairly recent development for oncologists to consider.3 Indeed, scien-
tists are still investigating many of the emerging options within the
field of oncofertility, in particular the options for women and girls not
yet of reproductive age. These include whole ovary and oocyte cry-
opreservation as well as the freezing of ovarian tissue. For boys not
yet of reproductive age, and thus unable to cryopreserve semen, inves-
tigational options include the freezing of testicular tissue.4
Health insurance itself is a relatively recent phenomenon, and even
more recent is the legal mandate that certain procedures be covered
by private health insurance.5 One of these more recent, and far from
universal, mandates is coverage of assisted reproductive treatment by
health insurance companies. In her commentary, Campo-Engelstein
argues for the need for an extension of insurance coverage to include
fertility preservation before cancer treatment as part of routine care. 6
2. Patient's Fact Sheet: Cancer and Fertility Preservation, AM. Soc'Y FOR REPROD. MED. (Jan.
2004), http://www.asrm.org/uploadedFiles/ASRM Content/Resources/PatientResources[Fact_
Sheets andInfoBooklets/cancer.pdf.
3. See generally Jacqueline S. Jeruss & Teresa K. Woodruff, Preservation of Fertility in Patients
with Cancer, 360 NEw ENG. J. MED. 902 (2009); Teresa K. Woodruff, The Emergence ofa New
Interdiscipline: Oncofertility, in ONCOFERTILITY: FERTILITY PRESERVATION FOR CANCER SURVI-
VORs 3 (Teresa K. Woodruff & Karrie Ann Snyder eds., 2007).
4. Mary E. Fallat & John Hutter, Preservation of Fertility in Pediatric and Adolescent Patients
with Cancer, 121 PEDIATRICS e1461, e1463 (2008); Pasquale Patrizio & Arthur L. Caplan, Ethical
Issues Surrounding Fertility Preservation in Cancer Patients, 53 CLINICAL OBSTETRICS & GYNE-
COLOGY 717, 718 (2010); see also Jeruss & Woodruff, supra note 3, at 909.
5. See generally PAUL STARR, REMEDY AND REACTION: THE PECULIAR AMERICAN STRUG-
GLE OVER HEALTH CARE REFORM (2011); see also PAUL OLIVER, CAL. HEALTHCARE FOUND.,
STATE EMPLOYER HEALTH INSURANCE MANDATES: A BRIEF HISTORY (2004), available at http:/
/www.masscare.org/wp-content/uploads/2007/05/CHCFEmployerMandatesHistory.pdf.
6. Lisa Campo-Engelstein, Commentary, Insurance Coverage for Cancer-Induced Conditions:
Comparing Fertility Preservation Technology and Breast Reconstructive Surgery, 61 DEPAUL L.
REV. 849 (2012).
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To do so, she compares the loss of fertility as part of cancer treatment
with the loss of a breast for cancer treatment, asserting that because
insurance companies pay for breast replacement surgery after cancer
therapy, these companies should envision fertility preservation as part
of this routine of care in order to create consistency and fairness in
coverage.
While Campo-Engelstein argues for fertility preservation as a mat-
ter of fairness in insurance coverage for cancer patients, Cholst is con-
cerned about the lack of regulation concerning another assisted
reproduction option for women who have undergone cancer treat-
ment: the use of donor oocytes.7 Cholst, speaking from the perspec-
tive of a clinician, is concerned that, while this form of reproduction is
viable, it lacks regulation-a concern for both the donor and the re-
cipient of the oocyte. She concludes, however, by noting that while
patients need support to adjust to their cancer diagnosis and progress
through their treatment, a "focus on technological solutions alone for
quality-of-life issues," such as the desire to parent, does not provide
the patient with a full perspective.8
In her article, Roberts, too, is concerned with the focus on techno-
logical solutions. But while both Campo-Engelstein and Cholst touch
upon the social context of oncofertility, for Roberts, the underlying
social structures of injustice is central to any conversation about the
ethics of oncofertility. 9 I will return to Roberts at the end of this
Commentary, and I am mindful of the larger social concerns Roberts
and others have brought to the fore about fertility preservation, such
as whether it reinforces the primacy of biological parenthood.10
But what I want to question in the remainder of this Commentary is
the framing of fertility preservation technologies within the narrative
of progress against cancer. In their recent article, Pasquale Patrizio
and Arthur Caplan argue that on an individual patient level, so long as
the standard of informed consent-with particular attention to the pe-
diatric patient-is met, there should be no ethical issues in offering
fertility preservation services to cancer patients." But they, as well
many others who have discussed fertility preservation, including the
7. Ina N. Cholst, Oncofertility: Preservation of Reproductive Potential, 61 DEPAUL L. REV.
763 (2012).
8. Id. at 774-75.
9. Dorothy E. Roberts, The Social Context of Oncofertility, 61 DEPAUL L. REV. 777 (2012).
10. See Shauna L. Gardino & Linda L. Emanuel, Choosing Life When Facing Death: Under-
standing Fertility Preservation Decision-Making for Cancer Patients, in ONCOFERTILITY: ETHI-
CAL, LEGAL, SOCIAL, AND MEDICAL PERSPECTIVEs 447, 447 (Teresa K. Woodruff et al. eds..
2010).
11. See Patrizio & Caplan, supra note 4, at 717-20.
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author, place the emergence of fertility preservation technologies
within the "progress against cancer" narrative. 12 Is it really progress
to be considering preserving the fertility of a young person diagnosed
with cancer nearly seventy-five years after the creation of the National
Cancer Institute and forty years after the "war on cancer" was
launched? Should we not primarily ask why a ten-year-old or twenty-
five-year-old is even getting cancer-with rates of some common
childhood cancers increasing-and what we should be doing to pre-
vent this diagnosis?13
Cancer has a long history, but here I am concerned with the more
recent development of our cultural acceptance of it within a biomedi-
cal and individual model: cancer is something we treat, either through
surgery, chemotherapy, radiation, or some combination rather than
something we collectively prevent. Beginning with the creation of the
National Cancer Institute in 1937, the foundation of the biomedical
model of cancer was established, and, though curtailed with the en-
trance of the United States in World War II, it rose again with the
influx of even more funding soon after the war's conclusion.14 The
strong investment in science by the federal government during the war
incited an interest in the expansive possibilities of scientific research
among Americans.' 5 The push to fund biomedical research grew out
of this larger cultural hope that the application of scientific knowledge
could improve and lengthen lives; this belief grew not just from the
advances themselves, but also in the belief in further advances and the
unlimited possibilities of science.16 This economic investment, sup-
ported by cultural belief, in the potential of scientific and medical re-
search profoundly altered Americans' postwar health expectations by
reinforcing the conviction that advancing scientific progress would
12. See Susan L. Barrett & Teresa K. Woodruff, Gamete Preservation, in ONCOFERTILITY:
ETHICAL, LEGAL, SOCIAL, AND MEDICAL PERSPECTIVES, supra note 10, at 25, 31; Patrizio &
Caplan, supra note 4, at 718.
13. Cf PRESIDENT'S CANCER PANEL, REDUCING ENVIRONMENTAL RISK, 2008-2009 ANNUAL
REPORT 111 (2010), available at http://deainfo.nci.nih.gov/advisory/pcp/annualReports/pcp08-
09rpt/PCP_- Report_08-09_508.pdf ("It is vitally important to recognize that children are far more
susceptible to damage from environmental carcinogens and endocrine-disrupting compounds
than adults.").
14. See SIDDHARTHA MUKHERJEE, THE EMPEROR OF ALL MALADIES: A BIOGRAPHY OF
CANCER 26 (2010); JAMES T. PATTERSON, THE DREAD DISEASE: CANCER AND MODERN AMERI-
CAN CULTURE 137 (1987); David Cantor, Introduction to Cancer Control and Prevention in the
Twentieth Century, in CANCER IN THE TWENTIETH CENTURY 5-6 (David Cantor ed., 2008).
15. See GERALD N. GROB, THE DEADLY TRUTH: A HISTORY OF DISEASE IN AMERICA 256
(2002).
16. See Judith P. Swazey & Rende C. Fox, Remembering the "Golden Years" of Patient-
Oriented Clinical Research: A Collective Conversation, 47 PERSP. BIOLOGY & MED. 487, 487-88
(2004).
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easily translate into medical progress, thus preserving and lengthening
lives. Scientific developments created an impression of inevitable pro-
gress, with illness and disability no longer viewed as inevitable parts of
life, but rather as problems to be overcome by scientific and medical
advances. Americans' belief in the unlimited potential of science and
its resultant medical advances was further influenced by dramatic
changes in the social and economic situation for many Americans, in
particular a rise in the standard of living. The combination of a higher
standard of living and a belief in science (as well as its clinical applica-
tions supporting a longer life) resulted in Americans spending more
on health care and a rise in the expectations of that care.17
Private organizations such as the American Cancer Society and, in-
creasingly in more recent decades, the pharmaceutical industry also
came to play a significant role in funding, thus establishing and rein-
forcing the biomedical model of cancer. Here, I simply note the in-
creased funding allocated by the federal government to this model as
a force behind the model." The U.S. government greatly intensified
the funding of biomedical cancer research as part of the beginnings of
a national medical research policy.19 Following World War II, the fed-
eral government dramatically amplified spending on cancer research:
in 1947, $14 million went to fund cancer research, and this grew to
$110 million in 1961, increasing to more than $200 million in 1970.20
In 1971, Congress and President Richard Nixon declared a "war on
cancer," resulting in the federal government doubling the amount of
biomedical research funding directed at the disease within one year.
Indeed, this war saw a vast amount of money directed to the biomedi-
cal research of cancer: in 1973, $500 million was allocated to the can-
cer research, then $600 million in 1974, with another $1.5 billion to be
spent over the next three years. 21 More recently, from 2005 through
2010, the budget for the National Cancer Institute has averaged $4.9
billion annually. 22
I am not questioning the spending of this money on biomedical re-
search, the resulting clinical advancements of which can be seen in the
control of many manifestations of cancer, including testicular cancer
and leukemia. I am not opposed to the biomedical model of cancer
17. See GROB, supra note 15, at 245; MUKHERJEE, supra note 14, at 121.
18. See R. F. Bud, Strategy in American Cancer Research After World War II: A Case Study, 8
Soc. STUD. Sci. 425, 431 (1978).
19. See GROB, supra note 15, at 256; MUKHERJEE, supra note 14, at 121.
20. PATTERSON, supra note 14, at 171-72, 245.
21. MUKHERJEE, supra note 14, at 188.
22. Cancer Research Funding, NAT'L CANCER INST. (June 2, 2011), http://www.cancer.gov/can-
certopics/factsheet/NCI/Fsl .pdf.
2012] 865
DEPAUL LAW REVIEW
that focuses on the individual. But this model developed, and is today
reinforced, largely at the expense of collective cancer prevention.
And this is what 1, following others before me, am questioning. This is
not to say that cancer prevention has been absent. Indeed, prevention
against cancer, with an emphasis on individual responsibility, has re-
mained a popular goal, though an elusive one, since the beginning of
the biomedical model of cancer. 23 In recent decades, increased atten-
tion has been devoted to examining behavioral factors as well as to
genetic susceptibility to cancer. 24 With respect to some cancers this
emphasis on personal behavior has worked, most notably the tie be-
tween smoking and lung cancer, just as it has in the case of early
screening (such as with cervical cancer) or with determining genetic
factors (such as with certain forms of breast cancer).
But despite a growing emphasis on genetic risk and lifestyle factors,
the dominant model remains the biomedical approach to a diagnosed
disease. Activists, especially within the last two decades and in partic-
ular environmental breast cancer activists, have begun questioning the
dominant biomedical model of addressing the disease after it develops
and instead argue for more attention paid to possible environmental
factors as a means to prevent the occurrence of cancer.25 Clinicians
and scientists have also recently expressed concern about the effects
of environmental factors; a recent President's Cancer Panel report
was centrally concerned that the "true burden of environmentally in-
duced cancer has been grossly underestimated." 2 6 Attention to the
possible environmental factors places the responsibility for dealing
with cancer not on individuals, but on the institutions responsible for
exposure to carcinogens in our homes, workplaces, and communities,
thus changing this model to include social structures as well as medical
ones. And it refocuses the model of cancer from attention to the dis-
ease once it has occurred to prevention of it from occurring.
Perhaps the increased awareness of the possibility of infertility for
children and young adults as a result of cancer treatments will initiate
a discussion about the limits of this biomedical model of cancer. Per-
haps the emergence of fertility preservation for children and young
adult cancer patients will initiate a discussion about why young people
are still getting cancer and thus increase the calls for research on the
23. GROB, supra note 15, at 260.
24. BARBARA L. LEY, FROM PINK TO GREEN: DISEASE PREVENTION AND THE ENVIRONMEN-
TAL BREAST CANCER MOVEMENT 5 (2009).
25. LEY, supra note 24, at 30-31.
26. Letter from LaSalle D. Leffall, Jr., Chair, President's Cancer Panel, to President Obama,
in PRESIDENT'S CANCER PANEL, supra note 13.
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prevention of cancer, and perhaps that discussion will take into ac-
count the social structure factors over which individuals have little
control. This, at any rate, is my hope.
But I worry that such optimism could be misplaced by our cultural
love affair with technological interventions to endemic problems, both
medical and otherwise. Instead of addressing the root of the problem,
we may continue along with the biomedical model and search for a
"cure" for cancer, accepting this as the definition of progress. I fear,
then, that fertility preservation technologies for cancer patients could
become one more example of the classically American solution to
medical and social problems: a technological fix to provide a solution
at the end, rather than acting to prevent a problem from the begin-
ning. As Roberts so compellingly and forcefully argues both in this
Issue and elsewhere, technological solutions to social problems often
results in further oppressing already-disadvantaged groups.27 Discuss-
ing this reliance on high-tech, end-point solutions rather than on pre-
vention is where, perhaps, the conversation regarding fertility
preservation should occur.
27. See DOROTHY ROBERTS, KILLING THE BLACK BODY: RACE, REPRODUCTION, AND THE
MEANING OF LIBERTY 269 (1997).
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